INOVIO To Test Its COVID-19 Vaccine Candidates Against Omicron Variant - Quick Facts

INOVIO (INO) said it is rapidly moving to evaluate the company's COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging Omicron variant. Also, INOVIO has started pre-clinical development of an Omicron-specific DNA vaccine candidate.

INOVIO plans to test clinical samples from its INO-4800 vaccine candidate as well as its pan-COVID-19 vaccine candidate INO-4802 against the Omicron variant to assess the generation of immune responses, with data expected in the coming weeks.

"We believe that INO-4800's ability to generate durable T cell responses, which could be resilient to changes in the SARS-CoV-2 virus, positions INO-4800 as a potentially important tool in the U.S. and international arsenal against both current and future variants," said, Joseph Kim, INOVIO's CEO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT